← Back to Search

Monoclonal Antibodies

Immunotherapy for Neuroblastoma

Phase 1
Waitlist Available
Research Sponsored by New Approaches to Neuroblastoma Therapy Consortium
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All patients must have at least one of the following: Recurrent/progressive disease, Refractory disease, Persistent disease
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to study registration
Must not have
Active or uncontrolled infection
Patient declines participation in NANT 2004-05
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from day 1 of protocol therapy through 30 days following end of protocol therapy
Awards & highlights

Summary

This trial will determine how well autologous expanded natural killer cells work with standard dosing of dinutuximab and with or without lenalidomide in treating children with neuroblastoma that has come back or does not respond to treatment.

Who is the study for?
This trial is for children with neuroblastoma that hasn't responded to initial treatments or has come back. They must have a certain type of tumor activity visible on specific scans, be under 30 years old, and have an expected lifespan of at least 12 weeks. Their heart, kidney, liver, and blood functions need to meet set levels. Pregnant or breastfeeding individuals can't join.
What is being tested?
The study tests the highest dose kids can handle of NK cells (a type of immune cell) combined with dinutuximab (an antibody therapy). It also looks at adding lenalidomide (a cancer drug) to this mix for those who've had no luck with standard treatments for their aggressive neuroblastoma.
What are the potential side effects?
Possible side effects include reactions related to the immune system like fever and chills from dinutuximab infusion; low blood counts leading to increased infection risk; tiredness; and skin rashes or other allergic reactions especially when starting lenalidomide.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My disease is either coming back, not responding, or has never fully gone away.
Select...
I have recovered from side effects of my previous cancer treatments.
Select...
I am not taking any other cancer treatments or undergoing radiotherapy while on this trial.
Select...
I have been diagnosed with neuroblastoma confirmed by tests.
Select...
My cancer shows up on specific scans and has been confirmed with a biopsy.
Select...
I am expected to live at least 12 weeks and can do some daily activities on my own.
Select...
I am 30 years old or younger.
Select...
I have a measurable cancer lesion.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have any ongoing or uncontrolled infections.
Select...
I have chosen not to participate in the NANT 2004-05 study.
Select...
My cancer has spread to my brain.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from day 1 of protocol therapy through 30 days following end of protocol therapy
This trial's timeline: 3 weeks for screening, Varies for treatment, and from day 1 of protocol therapy through 30 days following end of protocol therapy for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
MTD/RP2D determination
NK cell production feasibility
NK cell production feasibility (lowest dose level)
Secondary study objectives
Describe Hematological Toxicities
Describe Non-Hematological Toxicities
Overall Response

Trial Design

1Treatment groups
Experimental Treatment
Group I: NK cells with Dinutuximab & LenalidomideExperimental Treatment3 Interventions
Patients in this arm will receive a designated dose of NK cells on Day 5 and 17.5 mg/m2/dose of dinutuximab on Day 1-4. Patients on Dose Level 4 will also receive 25mg/m2/dose of Lenalidomide during Day -6 through 14 of treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NK Cells
2020
Completed Phase 2
~40
Dinutuximab
FDA approved
Lenalidomide
2005
Completed Phase 3
~1340

Find a Location

Who is running the clinical trial?

United TherapeuticsIndustry Sponsor
110 Previous Clinical Trials
14,513 Total Patients Enrolled
7 Trials studying Neuroblastoma
233 Patients Enrolled for Neuroblastoma
New Approaches to Neuroblastoma Therapy ConsortiumLead Sponsor
17 Previous Clinical Trials
1,683 Total Patients Enrolled
17 Trials studying Neuroblastoma
1,683 Patients Enrolled for Neuroblastoma
Nationwide Children's HospitalOTHER
347 Previous Clinical Trials
5,229,213 Total Patients Enrolled
4 Trials studying Neuroblastoma
179 Patients Enrolled for Neuroblastoma
~2 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top